Phoenix from the Ashes: Celebrating the 2023 North American Cystic Fibrosis Conference

Affiliations

¹ Imperial College and Royal Brompton Hospital London, United Kingdom.
² Department of Pediatrics University of Washington School of Medicine Seattle, Washington.
³ Pulmonology Institute and Cystic Fibrosis Center Carmel Medical Center and the Technion-Israel Institute of Technology Haifa, Israel.
⁴ Weill Cornell Medicine New York, New York.

Editorial

Andrew Bush et al. Am J Respir Crit Care Med. 2023.

. 2023 Nov 1;208(9):909-910.

doi: 10.1164/rccm.202309-1603ED.

¹ Imperial College and Royal Brompton Hospital London, United Kingdom.
² Department of Pediatrics University of Washington School of Medicine Seattle, Washington.
³ Pulmonology Institute and Cystic Fibrosis Center Carmel Medical Center and the Technion-Israel Institute of Technology Haifa, Israel.
⁴ Weill Cornell Medicine New York, New York.

No abstract available

Comment on

Affordable Cystic Fibrosis (CF) Transmembrane Conductance Regulator Modulator Drugs for CF: All CF Lives Worldwide Matter!
Zampoli M, Verstraete J, Baird C, Calligaro G, Morrow B. Zampoli M, et al. Am J Respir Crit Care Med. 2023 Nov 1;208(9):915-916. doi: 10.1164/rccm.202307-1200VP. Am J Respir Crit Care Med. 2023. PMID: 37549229 Free PMC article. No abstract available.
Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
Wang S, Niroula S, Hoffman A, Khorrami M, Khorrami M, Yuan F, Gasser GN, Choi S, Liu B, Li J, Metersky ML, Vincent M, Crum CP, Boucher RC, Karmouty-Quintana H, Huang HJ, Sheshadri A, Dickey BF, Parekh KR, Engelhardt JF, McKeon FD, Xian W. Wang S, et al. Am J Respir Crit Care Med. 2023 Nov 1;208(9):930-943. doi: 10.1164/rccm.202305-0818OC. Am J Respir Crit Care Med. 2023. PMID: 37695863 Free PMC article.
Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.
McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, Linnane B, Kirwan L, Rea D, O'Regan P, Semple T, Saunders C, Tiddens HAWM, McKone E, Davies JC; RECOVER Study Group. McNally P, et al. Am J Respir Crit Care Med. 2023 Nov 1;208(9):917-929. doi: 10.1164/rccm.202308-1317OC. Am J Respir Crit Care Med. 2023. PMID: 37703083 Clinical Trial.

1. De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med . 2016;4:662–674. - PubMed
1. McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, et al. Improvement in lung clearance index and chest CT scores with elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis aged 12 years and older: the RECOVER study. Am J Respir Crit Care Med . 2023;208:917–929. - PubMed
1. Wang S, Niroula S, Hoffman A, Khorrami M, Khorrami M, Yuan F, et al. Inflammatory activity of epithelial stem cell variants from cystic fibrosis lung is not resolved by CFTR modulators. Am J Respir Crit Care Med . 2023;208:930–943. - PMC - PubMed
1. Schaupp L, Addante A, Völler M, Fentker K, Kuppe A, Bardua M, et al. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J . 2023;62:2202153. - PubMed
1. Ronchetti K, Tame JD, Paisey C, Thia LP, Doull I, Howe R, et al. The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med . 2018;6:461–471. - PMC - PubMed